Therapeutic drug monitoring of teriflunomide: do plasma concentrations predict response to leflunomide in patients with rheumatoid arthritis?
arthritis
leflunomide
rheumatoid
Journal
Drug metabolism and personalized therapy
ISSN: 2363-8915
Titre abrégé: Drug Metab Pers Ther
Pays: Germany
ID NLM: 101653409
Informations de publication
Date de publication:
01 03 2023
01 03 2023
Historique:
received:
07
01
2022
accepted:
01
06
2022
pubmed:
24
8
2022
medline:
17
3
2023
entrez:
23
8
2022
Statut:
epublish
Résumé
Leflunomide is a commonly used treatment for rheumatoid arthritis. It acts by inhibiting dihydroorotate dehydrogenase through its active metabolite teriflunomide. The objective of the study was to investigate the relation between plasma-concentration of teriflunomide and disease-activity in rheumatoid arthritis. Data were collected from patients with rheumatoid arthritis on a stable leflunomide dose for at least 2 months. Socio-demographic data, disease characteristics and DAS28 score were recorded. Blood samples were taken for determination of teriflunomide concentration. A total of 32 serum concentration-time measurements were collected. The concentration of teriflunomide was positively correlated with disease duration of RA (r We did not find a concentration-effect-relationship. However, therapeutic drug monitoring of teriflunomide may be useful to ensure adherence and evaluate toxic-levels in case of adverse-events.
Identifiants
pubmed: 35998916
pii: dmdi-2021-0236
doi: 10.1515/dmpt-2021-0236
doi:
Substances chimiques
Leflunomide
G162GK9U4W
teriflunomide
1C058IKG3B
Isoxazoles
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
79-85Informations de copyright
© 2022 Walter de Gruyter GmbH, Berlin/Boston.
Références
Alfaro-Lara, R, Espinosa-Ortega, HF, Arce-Salinas, CA. PRECIS study group, all physicians belong to Division of Internal Medicine. Hospital Central Sur de Pemex. Systematic review and meta-analysis of the efficacy and safety of leflunomide and methotrexate in the treatment of rheumatoid arthritis. Reumatol Clínica 2019;15:133–9. https://doi.org/10.1016/j.reuma.2017.07.020 .
doi: 10.1016/j.reuma.2017.07.020
Smolen, JS, Landewé, RBM, Bijlsma, JWJ, Burmester, GR, Dougados, M, Kerschbaumer, A, et al.. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update. Ann Rheum Dis 2020;79:685–99. https://doi.org/10.1136/annrheumdis-2019-216655 .
doi: 10.1136/annrheumdis-2019-216655
Rozman, B. Clinical pharmacokinetics of leflunomide. Clin Pharmacokinet 2002;41:421–30. https://doi.org/10.2165/00003088-200241060-00003 .
doi: 10.2165/00003088-200241060-00003
Weber, W, Harnisch, L. Use of a population pharmacokinetic model to predict clinical outcome of leflunomide, a new DMARD in the treatment of rheumatoid arthritis. J Rheumatol 1997;2:1. (Eular 1997).
van Roon, EN, Jansen, TLTA, van de Laar, MAFJ, Janssen, M, Yska, JP, Keuper, R, et al.. Therapeutic drug monitoring of A77 1726, the active metabolite of leflunomide: serum concentrations predict response to treatment in patients with rheumatoid arthritis. Ann Rheum Dis 2005;64:569–74. https://doi.org/10.1136/ard.2004.025205 .
doi: 10.1136/ard.2004.025205
Chan, V, Charles, BG, Tett, SE. Population pharmacokinetics and association between A77 1726 plasma concentrations and disease activity measures following administration of leflunomide to people with rheumatoid arthritis. Br J Clin Pharmacol 2005;60:257–64. https://doi.org/10.1111/j.1365-2125.2005.02415.x .
doi: 10.1111/j.1365-2125.2005.02415.x
Wiese, MD, Hopkins, AM, King, C, Wechalekar, MD, Lee, A, Spargo, L, et al.. Precision medicine with leflunomide: consideration of DHODH haplotype and plasma teriflunomide concentration can substantially modify outcomes in patients with rheumatoid arthritis. Arthritis Care Res 2021;73:983–9. https://doi.org/10.1002/acr.24236 .
doi: 10.1002/acr.24236
Arnett, FC, Edworthy, SM, Bloch, DA, McShane, DJ, Fries, JF, Cooper, NS, et al.. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31:315–24. https://doi.org/10.1002/art.1780310302 .
doi: 10.1002/art.1780310302
El Meidany, YM, El Gaafary, MM, Ahmed, I. Cross-cultural adaptation and validation of an Arabic Health Assessment Questionnaire for use in rheumatoid arthritis patients. Joint Bone Spine 2003;70:195–202. https://doi.org/10.1016/s1297-319x(03)00004-6 .
doi: 10.1016/s1297-319x(03)00004-6
Fransen, J, van Riel, PLCM. The disease activity Score and the EULAR response criteria. Rheum Dis Clin N Am 2009;35:745–57. https://doi.org/10.1016/j.rdc.2009.10.001 .
doi: 10.1016/j.rdc.2009.10.001
Bohanec Grabar, P, Grabnar, I, Rozman, B, Logar, D, Tomšič, M, Šuput, D, et al.. Investigation of the influence of CYP1A2 and CYP2C19 genetic polymorphism on 2-Cyano-3-hydroxy-N-[4-(trifluoromethyl)phenyl]-2-butenamide (A77 1726) pharmacokinetics in leflunomide-treated patients with rheumatoid arthritis. Drug Metab Dispos 2009;37:2061–8. https://doi.org/10.1124/dmd.109.027482 .
doi: 10.1124/dmd.109.027482
Shi, J, Kovacs, SJ, Wang, Y, Ludden, TM, Bhargava, VO. Population pharmacokinetics of the active metabolite of leflunomide in pediatric subjects with polyarticular course juvenile rheumatoid arthritis. J Pharmacokinet Pharmacodyn 2005;32:419–39. https://doi.org/10.1007/s10928-005-0049-8 .
doi: 10.1007/s10928-005-0049-8
Fiehn, C, Rochel, E, Ho, AD, Max, R. Dose escalation of leflunomide (LEF) to 40 mg once daily in patients with rheumatoid arthritis and insufficient response to standard dose LEF. Ann Rheum Dis 2004;63:746–7. https://doi.org/10.1136/ard.2003.014217 .
doi: 10.1136/ard.2003.014217
Nguyen, M, Kabir, M, Ravaud, P. Short-term efficacy and safety of leflunomide in the treatment of active rheumatoid arthritis in everyday clinical use : open-label, prospective study. Clin Drug Invest 2004;24:103–12. https://doi.org/10.2165/00044011-200424020-00005 .
doi: 10.2165/00044011-200424020-00005
Weber, W, Harnisch, L. The population approach: measuring and managing variability in response, concentration and dose. In: COST B1 Medicine: European Cooperation in the Field of Scientific and Technical Research . Brussels: European Commission; 1997:238–44 pp.
Mladenovic, V, Domljan, Z, Rozman, B, Jajic, I, Mihajlovic, D, Dordevic, J, et al.. Safety and effectiveness of leflunomide in the treatment of patients with active rheumatoid arthritis. Results of a randomized, placebo-controlled, phase II study. Arthritis Rheum 1995;38:1595–603. https://doi.org/10.1002/art.1780381111 .
doi: 10.1002/art.1780381111
Ben Tekaya, A, Ben Hammamia, M, Tekaya, R, Ben Mrad, M, Denguir, R, Abdelmoula, L, et al.. Endovascular repair of inflammatory aortic aneuvrysm. Tunis Med 2017;95:229–3229878293.
pubmed: 29878293
Mahmoud, I, Tekaya, AB, Tekaya, R, Saidane, O, Gafsi, L, Benhamou, M, et al.. Pulmonary nodules in a patient with rheumatoid arthritis: Which diagnostic approach is the most appropriate? Caspian J Intern Med 2017;8:220–2.
Tekaya, R, Ben Tekaya, A, Sfar, I, Gafsi, L, Saidane, O, Dhaouadi, T, et al.. Interleukin-1 gene polymorphisms in axial spondyloarthritis Tunisian patients. Tunis Med 2020;98:986–91.